Zacks Investment Research
04 Jun 2026, 22:45 UTC · 2h ago
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Search tags
Zacks Investment Research
04 Jun 2026, 22:45 UTC · 2h ago
Search tags
Story key points
4 claims · impact-rated
Viking Therapeutics (VKTX) is expected to report an EPS of -$1.21, representing a 108.62% decrease compared to the same quarter last year. — A significant year-over-year drop in earnings per share typically triggers negative investor sentiment and downward price pressure.
-0.60The Zacks Consensus EPS estimate for Viking Therapeutics has decreased by 0.72% over the last 30 days. — Downward revisions by analysts generally signal deteriorating fundamentals or lower expectations for growth.
-0.30The Medical - Biomedical and Genetics industry is ranked in the bottom 37% of all industries tracked by Zacks. — Weak industry-wide rankings suggest systemic headwinds for companies operating within this specific sector.
-0.20Continue reading
6 related stories
Viking Therapeutics currently holds a Zacks Rank of #3 (Hold). — A 'Hold' rating suggests a neutral outlook and is unlikely to drive a strong directional move in the stock price.
Ticker attribution
Model heads
The company is facing a projected 108.62% fall in EPS and shares have depreciated over the past month.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
0 dimensions · 9 clusters
No impact vector found for this article yet.
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Zacks Investment Research
2h ago
